Abbott Recalls Zemplar Injection Due to Incorrect Vial Stoppers
Abbott Laboratories recalls specific lots of Zemplar (paricalcitol) Injection due to CGMP deviations involving potentially incorrect vial stoppers.
Use caution until it’s fixed
CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection.
Contact the company
What happened, in plain English
Abbott Laboratories is recalling Zemplar (paricalcitol) Injection, 5 mcg/mL in 2 mL multi-dose vials. The issue stems from potential CGMP deviations where a foreign or incorrect stopper may have been applied to the vials by third-party manufacturer Hospira. This affects NDC 0074-1658-05, Lot # 11-122-DK, with an expiration date of 10/13. Read more at govinfonow.com/recall/48887-abbott-laboratories-recalls-zemplar-paricalcitol-injection-5-mcg-ml-in.
Source Summary by GovInfoNow · govinfonow.com/recall/48887-abbott-laboratories-recalls-zemplar-paricalcitol-injection-5-mcg-ml-in · Updated October 13, 2026 · FDA enforcement record: FDA #D-1388-2012
Cite this page
“Abbott Recalls Zemplar Injection Due to Incorrect Vial Stoppers.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48887-abbott-laboratories-recalls-zemplar-paricalcitol-injection-5-mcg-ml-in. Based on FDA recall #D-1388-2012 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1388-2012%22&limit=1).
Why it’s dangerous
The primary risk is that an incorrect stopper was applied to the multi-dose vials. While the record does not specify the exact chemical or physical consequence of this deviation, it is classified as a CGMP (Current Good Manufacturing Practice) deviation, which can compromise product sterility or integrity.
Who’s affected
Patients prescribed Zemplar Injection who possess the specific recalled lot. The recall is nationwide and involves 121,000 vials distributed to pharmacies and healthcare facilities.
How to tell if you have this one
Check your medication for the brand name Zemplar (paricalcitol) Injection, 5 mcg/mL in 2 mL multi-dose vials. Verify the NDC is 0074-1658-05 and the Lot # is 11-122-DK with an expiration date of 10/13.
- Brand
Abbott Laboratories- Category
Drug
What to do — step by step
Check Your Medication
Verify if your Zemplar Injection matches NDC 0074-1658-05, Lot # 11-122-DK, Exp 10/13.
Contact Your Pharmacist
If you have the recalled product, contact your pharmacy or healthcare provider for instructions on return or replacement.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 7 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
What is the NDC number for the recalled product?
The National Drug Code (NDC) is 0074-1658-05.
Similar recalls
Other Abbott Laboratories recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1388-2012 (May 14, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1388-2012 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.